Aurobindo Pharma (AUROPHARMA) — Announcement

1 Announcement Neutral 📄 PDF

Aurobindo Pharma announced it has completed dematerialization of securities for the quarter ended June 30, 2026, as required under SEBI's Depositories and Participants Regulations, 2018. The company provided certificates from its RTA, KFin Technologies, confirming compliance with listing requirements across all exchanges where its shares are traded. This regulatory update ensures proper documentation of shareholding changes for investor transparency.

2 Announcement Neutral 📄 PDF

Aurobindo Pharma announced the completion of transferring its domestic branded generic pharmaceutical formulations business to its wholly owned subsidiary Auropharm Limited, effective July 1, 2026, as per the business transfer agreement finalized on April 6, 2026.

📊 Stock Analysis — AUROPHARMA ✨ Ask AI About This

About Aurobindo Pharma Limited (AUROPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹87,805.59 Cr P/E: 25.3

View full AUROPHARMA stock details →

📡 Get AI alerts when AUROPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AUROPHARMA — Free

💡 Ask AI about this filing

"How does this announcement affect Aurobindo Pharma Limited's outlook?" "What did Aurobindo Pharma Limited announce on 2 July 2026?" "Is this positive or negative for AUROPHARMA?"

Ask AI Free →

📊 More AUROPHARMA filings

See all AUROPHARMA filings →

🔥 Also filed on 2 July 2026

RAJRATAN Rajratan Global Wire Limited Annual Report RAJRATAN Rajratan Global Wire Limited Annual Report PSB Punjab & Sind Bank Annual Report PWL Physicswallah Limited Announcement PSB Punjab & Sind Bank Corporate Action RPGLIFE RPG Life Sciences Limited Annual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AUROPHARMA files new disclosures

Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.